Entries |
Document | Title | Date |
20080206364 | Topical nitric oxide as a treatment of autoimmune diseases - The present invention relates to compositions and methods for treatment of a patient affected with an autoimmune disorder, and in an embodiment, a skin-related autoimmune disorder. The treatment involves the application of gaseous nitric oxide to an affected patient, and in an embodiment, to the skin of an affected patient. | 08-28-2008 |
20080213403 | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide - The present invention provides a method for treating a pulmonary disease state in mammals by protecting indigenous in vivo levels of nitric oxide in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator, wherein the nitric oxide mediator is selected from the group consisting of α-keto acids having four or more carbon atoms, precursors of α-keto acids having four or more carbon atoms, and the salts thereof. | 09-04-2008 |
20080220095 | Red blood cells loaded with s-nitrosothiol and uses therefor - Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO | 09-11-2008 |
20080226751 | PHARMACEUTICAL COMPOSITION CONTAINING NITRATE SOURCE AND AN ACIDIFYING AGENT FOR TREATING SKIN ISCHAEMIA - The use of acidified nitrate as an agent to produce local production of nitrate oxide at the skin surface is described in the treatment of peripheral ischaemia and associated conditions. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. A barrier consisting of a membrane allows diffusions of the nitrate ions while preventing direct contact of the skin and acidifying agent. Amongst the many potential applications for the invention is the management of chronic skin wounds, peripheral ischaemia conditions such as Raynaud's phenomenon. Compositions and methods of use for these applications are described. | 09-18-2008 |
20080260865 | Methods for Treating Bacterial Respiratory Tract Infections in an Individual Using Acidified Nitrite - Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant | 10-23-2008 |
20080268071 | SUBSTITUTED CYCLOHEXANONES - Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 10-30-2008 |
20080317874 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) - A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal. | 12-25-2008 |
20090004298 | Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing - The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. | 01-01-2009 |
20090028966 | Methods for Introducing Reactive Secondary Amines Pendant to Polymers Backbones that are Useful for Diazeniumdiolation - Biocompatible polymers having polymer backbones with at least one secondary amine suitable for diazeniumdiolation are disclosed. Specifically, methods for providing secondary amines-containing polymers using epoxide-opening reactions are provided. More specifically, nitric oxide-releasing medical devices made using these polymers are disclosed. | 01-29-2009 |
20090053328 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use - The invention provides novel compositions and kits comprising at least one nitric oxide enhancing glutamic acid compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (n) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (O) the targeted delivery of compounds and nitric oxide to organs, cells or tissues containing the enzyme gamma-glutamyl transpeptidase. The nitric oxide enhancing glutamic acid compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. | 02-26-2009 |
20090061024 | COMPOSITIONS AND METHODS EMPLOYING NMDA ANTAGONISTS FOR ACHIEVING AN ANESTHETIC-SPARING EFFECT - Provided herein are compositions, combinations, and methods comprising NMDA antagonists including, but not limited to, NMDA glutamate receptor antagonists such as [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1-(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof, which are effective in reducing the amount of anesthetic required to maintain anesthesia (i.e. to achieve an anesthetic-sparing effect). | 03-05-2009 |
20090098219 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 04-16-2009 |
20090110756 | Methods and Compositions Related to PLUNC Surfactant Polypeptides - Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide. | 04-30-2009 |
20090130233 | Two part lotion - The present invention provides a composition, substantially a lotion, containing a source of nitrite ions and water. The composition, substantially a lotion, is preferably provided in two distinct and separate formulations. One of these formulations may or may not contain a source of nitrite ions. The composition is easily washed off with soap and water and is useful in preventing or treating bacterial, viral, parasitic or fungal infections. Further, the invention provides methods for preventing or treating bacterial, viral, parasitic or fungal infections by applying a pharmaceutically effective amount of the composition topically to the skin. Still further, the invention provides a kit comprising the composition of according to the invention together with instructions for applying the composition topically. | 05-21-2009 |
20090142416 | Methods for the treatment of HIV and other viruses - A treatment for the persons infected with viruses such as HIV. The method takes Advantage of the anesthetic membrane effect brought about by certain gases under pressure. A patient infected with HIV, for example, is placed in a pressurized chamber and exposed to one or more gases under pressure. In this environment, molecules or compounds bind to specific attachment sites on surfaces of host cells and on the virus. These attachment sites are the same sites that are required by the virus to attach to host cells during the virus's replication process. The result is that viruses are prevented from replicating. In the case of HIV, without replication, the virus is also prevented from mutating. This deleterious effect on the virus allows the body's immune system to reconstitute itself in numbers sufficient to cause clinical remission. The present method generally comprises the steps of selecting the gases, pressures and duration to be used inside a pressurized chamber, and exposing the patient to the selected conditions. | 06-04-2009 |
20090191284 | USE OF NITROANILINE DERIVATIVES FOR THE PRODUCTION OF NITRIC OXIDE - The present disclosure relates to the use of a nitroaniline derivative of Formula (I) for the production of nitric oxide and for the preparation of a medicament for the treatment of a disease wherein the administration of nitric oxide is beneficial. The present disclosure furthermore relates to a method for the production of NO irradiating a nitroaniline derivative of Formula (I), a kit comprising a nitroaniline derivative of Formula (I) and a carrier and to a system comprising a source of radiations and a container associated to a nitroaniline derivative of Formula (I). In Formula (I), R and R | 07-30-2009 |
20090214674 | Methods and Compositions for Regulating Biofilm Development - The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The invention also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant. The invention also relates to compositions for promoting dispersal of, or preventing formation of microbial biofilms, or for maintaining or enhancing or maintaining and enhancing the functioning of microbial biofilms. | 08-27-2009 |
20090232909 | Method for determining physiological effects of hemoglobin - NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a cooperative manner, nitrosylates hemoglobin thiols, or reacts with liberated superoxide in solution. The distribution of minor forms of hemoglobin can be tested and the results can be used to predict whether a composition of hemoglobin will scavenge, load, eliminate, or donate NO. Hemoglobin thus serves to regulate the chemistry of NO. SNO-hemoglobin transfers NO equivalents to the red blood cell anion transport protein AE1, which serves to export NO from red blood cells. Regulation of AE1 function is the basis for methods of therapy to affect levels of NO or its biological equivalent. | 09-17-2009 |
20090246296 | METHOD OF TREATING ISCHEMIA/REPERFUSION INJURY WITH NITROXYL DONORS - Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO. | 10-01-2009 |
20090252816 | Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide - The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen. | 10-08-2009 |
20090297634 | Compositions for sustrained release of nitric oxide, methods of preparing same and uses thereof - The invention provides compositions for releasing nitric oxide (NO) comprising a matrix that encapsulates nitric oxide. Nitric oxide is released when the composition is exposed to an aqueous environment. The invention further provides methods of preparing the compositions and uses of the compositions for treating infections and disorders. | 12-03-2009 |
20090317492 | Therapeutic Composition and Use - The use of liquid formulations in the preparation of a medicament for the prevention and treatment of oral, gastric and digestive infections and in particular for the prevention of ventilator associated pneumonia as well as liquid enteral and parenteral tube feeding compositions. The feeding compositions are suitable for use in the prevention of ventilator associated pneumonia. | 12-24-2009 |
20100003349 | PORTABLE, NITRIC OXIDE GENERATOR - An apparatus for portable delivery of nitric oxide without the need for pressurized tanks, power supplies, or other devices provides a single therapy session by triggering a heater to heat a reaction chamber. A piercing assembly may trigger to open sealed containers, such as bags, of liquid water or salt water in order to activate the heaters. Upon addition of liquid such as water or salt water to a chemically reactive heating element, heat is generated to activate the chemicals generating nitric oxide within a sealed reactor. Upon triggering, liquid containers are unsealed, the liquid drains down to initiate reaction of the heating chemicals, and the heat begins to penetrate the reactor. The reactor, in turn, heats its contents, which react to form nitric oxide expelled by the reactor to a line feeding a cannula for therapy. | 01-07-2010 |
20100015253 | Treatment of nail infections with no - Nitrogen oxide generating compositions are useful in the treatment of subungual infections, as NO has surprisingly been found to be able to penetrate the nail to exert an anti-fungal effect. | 01-21-2010 |
20100040703 | USE OF NITRIC OXIDE - The present invention relates to uses, compositions, devices, and methods involving the utilisation of nitric oxide to hinder, impede, inhibit, or prevent transmission of infectious viral particles to host cells. | 02-18-2010 |
20100055206 | Use of ribose in first response to acute myocardial infarction - D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour. | 03-04-2010 |
20100104667 | Conversation of nitrogen dioxide (NO2) to nitric oxide (NO) - A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal. | 04-29-2010 |
20100112095 | BIFUNCTIONAL MATERIAL FOR NITRIC OXIDE STORAGE AND PRODUCTION AND USE THEREOF IN THERAPY - The present invention relates to a bifunctional material which comprises copper and which is capable of storing nitric oxide (NO), as well as catalytically producing nitric oxide from a suitable precursor. The material typically includes a zeolite and the copper may be part of or separate from the zeolite. In this manner the material may include a single bifunctional material; that is, a material which is capable of both storing NO and catalytically producing NO, such as Cu-MFI or Cu—X. Alternatively the material may include at least two components, a first component to store NO, such as a zeolite Zn-LTA, and a further component including Cu(I), such as Cu | 05-06-2010 |
20100129474 | AGRICULTURAL TREATMENT - A method for the control of microorganisms, fungi or oomycetes in agriculture, said method comprising applying to plants or to the environment thereof, an anti-microbial, anti-fungal or anti-oomycetes effective amount of a combination of: (i) an agriculturally acceptable acidifying agent, and (ii) an agriculturally acceptable source of nitrite ions or a nitrate precursor thereof, wherein the combination of (i) and (ii) acts as a source of nitric oxide. Systems and compositions for use in this method are also described and claimed. | 05-27-2010 |
20100136142 | SUBSTITUTED-4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF - The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 06-03-2010 |
20100143504 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE PROTECTION AND REGENERATION - In various aspects the present inventions provide compositions and methods for treatment of cardiac conditions. In various embodiments, the present inventions provide methods for treating a cardiac condition comprising the step of administering in a therapeutically effective amount the substantially cell free solution of an amphiphilic self-assembling peptide to a site of cardiac tissue that has been injured due to one or more of atrial fibrillation, acute myocardial infarction; valve disease, pericardial disease, congenital heart disease, congestive heart failure, and embolism. | 06-10-2010 |
20100143505 | INDANONE INHIBITORS OF ACETYLCHOLINESTERASE - The present invention relates to new indanone inhibitors of acetylcholinesterase, pharmaceutical compositions thereof, and methods of use thereof. | 06-10-2010 |
20100173019 | METHOD OF STABILIZING HUMAN EYE TISSUE BY REACTION WITH NITRITE AND RELATED AGENTS SUCH AS NITRO COMPOUNDS - A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma. | 07-08-2010 |
20100189817 | Treating Glaucoma - Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual. In yet another embodiment, the invention is directed to methods of treating glaucomatous optic neuropathy in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucomatous optic neuropathy in the individual. The method can further comprise administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's lamina cribrosa (LC). | 07-29-2010 |
20100203172 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 08-12-2010 |
20100239692 | METHODS OF TREATMENT FOR HEMOLYSIS - Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor. | 09-23-2010 |
20100247681 | NITRITE AND NITRITE-METHEME THERAPY TO DETOXIFY STROMA-FREE HEMOGLOBIN BASED BLOOD SUBSTITUTES - This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject. | 09-30-2010 |
20100247682 | USE OF NITRITE SALTS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS - It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm. | 09-30-2010 |
20100278942 | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE THROMBOLYTIC AGENT (A) AND AT LEAST ONE GAS (B) SELECTED FROM THE GROUP CONSISTING OF NITROUS OXIDE, ARGON, XENON, HELIUM, NEON - The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia. | 11-04-2010 |
20100323036 | Nitric Oxide Therapies - A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition. | 12-23-2010 |
20100330206 | METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION - The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide. | 12-30-2010 |
20100330207 | METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION - The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide. | 12-30-2010 |
20110003016 | HAIR CARE COMPOSITION - A hair treatment composition comprising a trichogenic material and an anti-dandruff agent. | 01-06-2011 |
20110070318 | SKIN DRESSINGS - A skin dressing is provided comprising a first component comprising a source of protons, a second component comprising a nitrite salt, the dressing comprising a non-thiol reductant, such that, when the first and second components are brought together and applied to a skin site the nitrite reacts to generate nitric oxide, increasing the pH of the dressing in contact with the skin from an acidic value to a more neutral value. | 03-24-2011 |
20110081427 | Nitroxyl Progenitors in the Treatment of Heart Failure - Administration of an HNO/NO | 04-07-2011 |
20110159116 | BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES - The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework. | 06-30-2011 |
20110206781 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH - Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway. | 08-25-2011 |
20110287113 | TREATMENT OF PSORIASIS - The invention relates to an aqueous composition capable of delivering nitric oxide for use in the treatment of psoriasis, particularly plaque psoriasis, e.g. by application of a skin dressing. | 11-24-2011 |
20120003329 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension - This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A | 01-05-2012 |
20120027877 | NITRIC OXIDE GENERATOR AND NON-DELIQUESCENT TABLET FOR USE IN SAME - An apparatus to generate nitric oxide is disclosed in one embodiment in accordance with the invention as including a heat source and a vessel containing the heat source. A tablet may be placed within the vessel such that it is in thermal communication with the heat source to receive heat therefrom. The tablet may contain reactants that are substantially non-deliquescent and form nitric oxide in response to heat from the heat source. | 02-02-2012 |
20120034321 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention provides methods for treating ophthalmic disorders comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. | 02-09-2012 |
20120045528 | USE OF N20 GAS FOR TREATING CHRONIC PAIN - The invention relates to a gas mixture that contains nitrous oxide (N | 02-23-2012 |
20120064180 | USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES - The present invention relates to a method for terminating dormancy in an invertebrate, wherein said invertebrate is brought in contact with nitric oxide and/or a nitric oxide donor. The method can be used in pest management of unfavourable species, in eliminating dormant stages of aquatic invertebrates in ballast water in promoting termination of dormancy in beneficial species and/or in stimulating production of live food in aquacultures. | 03-15-2012 |
20120093948 | Nitric Oxide Treatments - Portable and pure nitric oxide delivery systems can be used to treat a variety of patient conditions. | 04-19-2012 |
20120107423 | Methods of Using Inhaled Nitric Oxide Gas for Treatment of Acute Respiratory Distress Syndrome - The present invention provides a treatment of acute respiratory distress syndrome (ARDS) using short term dosing of nitric oxide. | 05-03-2012 |
20120114768 | ANGIOGENESIS REGULATING COMPOSITION AND METHOD FOR REGULATING ANGIOGENESIS - An angiogenesis regulating composition used to treat/prevent an angiogenic disease in a subject, that contains in an effective amount at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, and an angiogenesis regulation method administering to a subject a composition containing as an active ingredient at least one of nitrate. nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, provide a composition effective in treating and preventing angiogenic diseases, that can medically control angiogenic diseases, and medically regulate angiogenesis in ophthalmologic diseases in particular, and allows treatment without inhibiting physiological neovascularization, with a limited side effect and significantly safely, and an angiogenesis regulation method using the same. | 05-10-2012 |
20120135092 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS - Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. In some embodiments, the compound is a N | 05-31-2012 |
20120177753 | MULTIFUNCTIONAL TOPICAL FORMULATION FOR THE TREATMENT OF ACNE VULGARIS AND OTHER SKIN CONDITIONS - A two-part aqueous composition for treating skin ailments, such as acne vulgaris, includes an acidic part having salicylic acid and an α-hydroxy acid, and an alkaline part having an alkaline nitrite salt. The α-hydroxy acid is preferably glycolic acid, lactic acid, malic acid, mandelic acid or a combination thereof. The alkaline nitrite salt is preferably sodium nitrite. The acidic part and the alkaline part are an acidic aqueous solution and an alkaline aqueous solution, respectively, which may either be mixed with one another then applied to an affected portion of a patient's skin or, alternatively, may be sequentially applied to the affected portion of the patient's skin, preferably within 15 minutes of one another. | 07-12-2012 |
20120195983 | TREATMENT OF SPECIFIC CARDIOVASCULAR CONDITIONS WITH NITRITE - It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm. | 08-02-2012 |
20120201906 | NOVEL MEDICAL USES FOR NO AND NO DONOR COMPOUNDS - A body part is preserved using nitric oxide and/or a nitric oxide donor that does not directly release nitric oxide or a red blood cell nitrosylating agent, preferably ethyl nitrite to facilitate oxygen supply. A subject at risk for developing high altitude illness is administered a red blood nitrosylating agent in gaseous form that does not directly release nitric oxide, preferably ethyl nitrite. | 08-09-2012 |
20120201907 | Nitroxyl Progenitors in the Treatment of Heart Failure - Administration of an HNO/NO | 08-09-2012 |
20120321724 | Method of Measuring and Monitoring In Vivo Nitrite Levels - A method of measuring in vivo nitric oxide and nitrite levels in individuals by providing a salivary nitrite test substrate, testing salivary nitrite levels with the test substrate, measuring nitrite levels detected in the testing; and correlating the measured nitrite levels with in vivo nitric oxide bio-availability. | 12-20-2012 |
20130017277 | CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO) - Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. | 01-17-2013 |
20130022691 | Nitric Oxide Generation, Dilution, and Topical Application Apparatus and Method - An apparatus for controlled delivery of nitric oxide. A pump draws air through an activated carbon filter and into a reaction chamber. The generation of nitric oxide occurs in the reaction chamber. A second pump draws the gas in the reaction chamber through a calcium hydroxide filter and delivers the nitric oxide through an orifice, or aperture, that controls the flow of nitric oxide delivered. The nitric oxide is filtered through a calcium hydroxide filter just prior to being made available for various nitric oxide therapies. Topical applications that provide a nitric oxide therapy to a surface are also provided. | 01-24-2013 |
20130040000 | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas - Disclosed are methods of reducing the risk of occurrence of pulmonary edema associated with a medical treatment comprising inhalation of nitric oxide gas. | 02-14-2013 |
20130059017 | TOPICAL NITRIC OXIDE SYSTEMS AND METHODS OF USE THEREOF - The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term. Thus, for example, a composition of the invention may exhibit a long shelf life, with little loss or reaction of nitric oxide. This may be particularly useful for certain applications such as consumer products, including those described herein. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 03-07-2013 |
20130071494 | NITRITE FORMULATIONS AND THEIR USE AS NITRIC OXIDE PRODRUGS - Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided. | 03-21-2013 |
20130078321 | METHODS FOR TREATING PATIENTS WHO ARE CANDIDATES FOR INHALED NITRIC OXIDE TREATMENT - Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema. | 03-28-2013 |
20130089629 | KIT FOR THE TREATMENT OF ONYCHOMYCOSIS BY NITRIC OXIDE - A kit for the treatment of onychomycosis by nitric oxide, including: a) a pre-treatment part comprising a pharmaceutically acceptable acidifying agent in an amount sufficient to loosen up the superficial outer nail plate layer, b) a treatment part comprising a pharmaceutically acceptable nitrite and at least one polysaccharide or a NO eluting polymer in one container and ascorbic acid in another container in amounts sufficient to produce nitric oxide in an amount that reduces and/or eliminates the onychomycosis upon being mixed and c) at least two devices suitable to apply a) and b) at the treatment site and upon treatment secure that the treatment site is substantially sealed. | 04-11-2013 |
20130095194 | USE OF INHALED NITROUS OXIDE OR XENON FOR PREVENTING NEUROPATHIC PAIN CAUSED BY CANCER CHEMOTHERAPY - The invention relates to a gaseous inhalable medicament containing xenon or N | 04-18-2013 |
20130108715 | Therapeutic Agent and Therapeutic Device for Alleviating Ischemia-Reperfusion Injury | 05-02-2013 |
20130171272 | METHOD FOR GENERATING NITRIC OXIDE - The present invention relates to a method for generating nitric oxide, in particular for therapeutic applications, which comprises the steps of: guiding a process gas into a reaction chamber ( | 07-04-2013 |
20130202721 | SENSORS FOR DETECTING SUBSTANCES IN BODILY FLUIDS - A system is disclosed that extracts bodily fluid to a reaction chamber for monitoring a substance or property of the patient fluid. In one embodiment, a pump is used to advance the sample of bodily fluid through a filter to produce a filtrate. Another pump advances filtrate into the reaction chamber, while another pump advances reactant into the reaction chamber. A sensor in communication with the reaction chamber determines a concentration of nitric oxide or one of its metabolic products. Methods are also disclosed. | 08-08-2013 |
20130209584 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 08-15-2013 |
20130230606 | METHODS AND COMPOSITIONS FOR REGULATING BIOFILM DEVELOPMENT - The present disclosure relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, including: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The disclosure also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant. The disclosure also relates to compositions for promoting dispersal of, or preventing formation of microbial biofilms, or for maintaining or enhancing or maintaining and enhancing the functioning of microbial biofilms. | 09-05-2013 |
20130251823 | ANGIOGENESIS REGULATING COMPOSITION AND METHOD FOR REGULATING ANGIOGENESIS - An angiogenesis regulating composition used to treat/prevent an angiogenic disease in a subject, that contains in an effective amount at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, and an angiogenesis regulation method administering to a subject a composition containing as an active ingredient at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, provide a composition effective in treating and preventing angiogenic diseases, that can medically control angiogenic diseases, and medically regulate angiogenesis in ophthalmologic diseases in particular, and allows treatment without inhibiting physiological neovascularization, with a limited side effect and significantly safely, and an angiogenesis regulation method using the same. | 09-26-2013 |
20130273179 | SYSTEM AND METHOD FOR IMPROVING OUTCOME OF CEREBRAL ISCHEMIA - A method for improving outcome following cerebral ischemia is provided. The method includes delivering nitric oxide into the nasal cavity for absorption into the brain through the nasal vasculature and preventing the inhalation of nitric oxide into the lungs to prevent pulmonary vasodilatation. | 10-17-2013 |
20130273180 | SYSTEM AND METHOD FOR IMPROVING OUTCOME OF CEREBRAL ISCHEMIA - A method for improving outcome following cerebral ischemia is provided. The method includes delivering nitric oxide into the nasal cavity for absorption into the brain through the nasal vasculature and maintaining the nitric oxide in the nasal cavity. | 10-17-2013 |
20130302447 | System And Method Of Administering A Pharmaceutical Gas To A Patient - A method and system for delivering a pharmaceutical gas to a patient. The method and system provide a known desired quantity of the pharmaceutical gas to the patient independent of the respiratory pattern of the patient. The preferred pharmaceutical gases are CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate any further delivery of the pharmaceutical gas or can activate an alarm to alert the user that the known quantity has been delivered. The system also has alarm functions to alert the user of possible malfunctions of the system. | 11-14-2013 |
20130309328 | METHOD OF DETERMINING VASOREACTIVITY USING INHALED NITRIC OXIDE - A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction. | 11-21-2013 |
20130309329 | METHODS AND COMPOSITIONS FOR TREATING, REDUCING OR PREVENTING DETERIORATION OF THE VISUAL SYSTEM OF ANIMALS - Methods and compositions for treating, reducing, or preventing deterioration of at least one component of the visual system of an animal are disclosed. The methods comprise administering to the animal a composition comprising UFA and NORC in an amount effective to treat, reduce, or prevent deterioration of at least one component of the visual system. Methods extending the prime years of an animal's life, improving the quality of life, and promoting health and wellness of an animal using compositions comprising UFA and NORC are also disclosed. | 11-21-2013 |
20140017342 | NITRITE AND NITRITE-METHEME THERAPY TO DETOXIFY STROMA-FREE HEMOGLOBIN BASED BLOOD SUBSTITUTES - This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject. | 01-16-2014 |
20140023730 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 01-23-2014 |
20140057001 | METHODS OF DECREASING SEBUM PRODUCTION IN THE SKIN - Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject. In some embodiments, the nitric oxide source includes small molecule and/or macromolecular NO-releasing compounds, | 02-27-2014 |
20140120184 | ARGON-BASED INHALABLE GASEOUS MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROINTOXICATIONS - The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms. | 05-01-2014 |
20140127329 | USE OF NITRITES FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY, AGE ASSOCIATED DEMENTIA, AND COGNITIVE DECLINE - The present invention relates to the medical use of nitrites, such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, compositions, or prodrugs thereof, in the treatment of conditions that benefit from increased cerebral vascular flow. The pharmaceutical compositions used in these methods, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 05-08-2014 |
20140127330 | METHOD OF MIXING GASES INCLUDING NITRIC OXIDE - A method of delivering nitric oxide can include mixing a first gas including oxygen and a second gas including a nitric oxide-releasing agent within a receptacle to form a gas mixture, where the receptacle includes an inlet, an outlet and a reducing agent, contacting the nitric oxide-releasing agent in the gas mixture with the reducing agent to generate nitric oxide, and delivering the gas mixture including nitric oxide from the receptacle to a mammal. | 05-08-2014 |
20140178504 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF - The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework. | 06-26-2014 |
20140212516 | NITRIC OXIDE GENERATOR AND NON-DELIQUESCENT TABLET FOR USE IN SAME - An apparatus to generate nitric oxide is disclosed in one embodiment in accordance with the invention as including a heat source and a vessel containing the heat source. A tablet may be placed within the vessel such that it is in thermal communication with the heat source to receive heat therefrom. The tablet may contain reactants that are substantially non-deliquescent and form nitric oxide in response to heat from the heat source. | 07-31-2014 |
20140242194 | USE OF NITRITE SALTS IN TREATING TISSUE DAMAGE - Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment. | 08-28-2014 |
20140255518 | Treatment and Prevention of Gastrointestinal Syndrome - Compositions comprising a guanylyl cyclase C agonist in an amount effective to protect intestinal tissue against radiation or chemotherapy and methods of using such compositions to prevent GI syndrome in cancer patient undergoing radiation or chemotherapy and in individuals exposed to or susceptible to exposure to radiation are disclosed. | 09-11-2014 |
20140271934 | PEPTIDE SYSTEMS AND METHODS FOR METABOLIC CONDITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 09-18-2014 |
20140271935 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 09-18-2014 |
20140271936 | MEMORY OR LEARNING USING PEPTIDE AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 09-18-2014 |
20140271937 | BRAIN AND NEURAL TREATMENTS COMPRISING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 09-18-2014 |
20140271938 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES - The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 09-18-2014 |
20140271939 | CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO) - Various systems, devices, NO | 09-18-2014 |
20140314880 | NITRIC OXIDE GENERATION, DILUTION, AND TOPICAL APPLICATION APPARATUS AND METHOD - An apparatus for controlled delivery of nitric oxide. A pump draws air through an activated carbon filter and into a reaction chamber. The generation of nitric oxide occurs in the reaction chamber. A second pump draws the gas in the reaction chamber through a calcium hydroxide filter and delivers the nitric oxide through an orifice, or aperture, that controls the flow of nitric oxide delivered. The nitric oxide is filtered through a calcium hydroxide filter just prior to being made available for various nitric oxide therapies. Topical applications that provide a nitric oxide therapy to a surface are also provided. | 10-23-2014 |
20140314881 | NOVEL MEDICAL USES FOR NO AND NO DONOR COMPOUNDS - A body part is preserved using nitric oxide and/or a nitric oxide donor that does not directly release nitric oxide or a red blood cell nitrosylating agent, preferably ethyl nitrite to facilitate oxygen supply. A subject at risk for developing high altitude illness is administered a red blood nitrosylating agent in gaseous form that does not directly release nitric oxide, preferably ethyl nitrite. | 10-23-2014 |
20140335207 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD - A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance. | 11-13-2014 |
20140363525 | Method And Apparatus For Generating Nitric Oxide For Medical Use - A method and system for generating and delivering nitric oxide directly to a patient. A reaction chamber is provided that is located at or in close proximity to the patient and reactants within the reaction chamber react together to produce a predetermined amount of nitric oxide. The reaction is controlled by metering at least one of the reactants into the reaction chamber to generate a predetermined quantity of nitric oxide as required by the patient. The reactants can include a nitrite salt, such as sodium nitrite, and a reductant such as ascorbic acid, maleic acid or a mixture thereof. By generating and delivering the nitric oxide directly to the patient in close proximity thereto, the formation of NO | 12-11-2014 |
20140370125 | METHOD FOR PRODUCING NO/N2 GASEOUS MIXTURES INTENDED FOR THE MEDICAL FIELD - The invention relates to a method for producing an NO/N | 12-18-2014 |
20140377377 | METHODS OF REDUCING THE RISK OF MORTALITY ASSOCIATED WITH A MEDICAL TREATMENT - Disclosed are methods of treatment that permit a reduction of risk of mortality in infants who are candidates for treatment with inhaled nitric oxide, by identifying a subset of such infants who are at an increased risk of mortality upon treatment with inhaled nitric oxide; also disclosed are related systems for use in administering inhaled nitric oxide and methods of distributing a pharmaceutical product. | 12-25-2014 |
20140377378 | METHODS OF DISTRIBUTING A PHARMACEUTICAL PRODUCT COMPRISING NITRIC OXIDE GAS FOR INHALATION - Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation. The methods include, for example, obtaining a cylinder containing nitric oxide gas and supplying the cylinder to a medical provider along with instructions regarding how to administer the gas safely to pediatric patients, the instructions including information that patients who have pre-existing left ventricular dysfunction and are administered inhaled nitric oxide may experience pulmonary edema. | 12-25-2014 |
20150010655 | SYSTEMS AND METHODS FOR TREATMENT OF ACNE VULGARIS AND OTHER CONDITIONS WITH A TOPICAL NITRIC OXIDE DELIVERY SYSTEM - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010656 | TREATMENT OF SKIN AND SOFT TISSUE INFECTION WITH NITRIC OXIDE - The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as | 01-08-2015 |
20150010657 | METHODS AND SYSTEMS FOR TREATMENT OF INFLAMMATORY DISEASES WITH NITRIC OXIDE - The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010658 | TREATMENT AND PREVENTION OF LEARNING AND MEMORY DISORDERS - The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010659 | METHODS AND COMPOSITIONS FOR MUSCULAR AND NEUROMUSCULAR DISEASES - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010660 | COMPOSITIONS AND METHODS FOR TREATMENT OF OSTEOPOROSIS AND OTHER INDICATIONS - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010661 | TECHNIQUES AND SYSTEMS FOR TREATMENT OF NEUROPATHIC PAIN AND OTHER INDICATIONS - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150010662 | CANCER TREATMENTS AND COMPOSITIONS FOR USE THEREOF - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 01-08-2015 |
20150017267 | Treatment of Inflammatory Disorders in Non-Human Mammals - The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents. | 01-15-2015 |
20150044305 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 02-12-2015 |
20150050361 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION - The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions. | 02-19-2015 |
20150072022 | FRACTIONAL C-REACTIVE PROTEIN (fracCRP) ANTIBODIES AND ASSAYS - Antibodies and antigen-binding fragments of antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments. | 03-12-2015 |
20150072023 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 03-12-2015 |
20150072024 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 03-12-2015 |
20150072025 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 03-12-2015 |
20150086651 | S-NITROSOTHIOL-GENERATING SKIN DRESSINGS - The present disclosure relates to a skin dressing adapted, on activation, to generate one or more S-nitrosothiols by reaction between a thiol and a nitrite salt in the skin dressing for delivery of nitric oxide to a body site. The skin dressing comprises a source of Cu | 03-26-2015 |
20150110899 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 04-23-2015 |
20150125552 | NO/Nitrogen Gaseous Mixture With A High NO Content For The Treatment Of Severe Hypoxemic Respiratory Failure - The invention concerns a gaseous medicine comprising a mixture of nitrogen monoxide (NO) and nitrogen (N2) for use by inhalation for the treatment of hypoxemic respiratory failure linked to pulmonary vasoconstriction in humans, said gaseous mixture containing between 1200 and 4500 ppm by volume (ppmv) of nitrogen monoxide (NO) and said hypoxemic respiratory failure being chosen from acute respiratory distress syndrome (ARDS) or persistent pulmonary hypertension of the newborn infant (PPHN). | 05-07-2015 |
20150125553 | USE OF NITRITE SALTS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS - It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm. | 05-07-2015 |
20150140131 | Therapeutic Composition And Use - The use of liquid formulations in the preparation of a medicament for the prevention and treatment of oral, gastric and digestive infections and in particular for the prevention of ventilator associated pneumonia as well as liquid enteral and parenteral tube feeding compositions. The feeding compositions are suitable for use in the prevention of ventilator associated pneumonia. | 05-21-2015 |
20150290417 | System and Method for High Concentration Nitric Oxide Delivery - The present invention relates to systems and methods for administering high concentrations of nitric oxide (NO) gas to a patient without the need to provide supplemental oxygen to the patient. The systems and methods can be used to administer high therapeutic amounts of NO gas, for example a gas comprising 160 ppm NO, while forming little or no residual nitrogen dioxide (NO | 10-15-2015 |
20150328256 | Compositions And Methods For Treating Diseases Or Disorders Using Extended Release Nitric Oxide Releasing Solutions - The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. | 11-19-2015 |
20150328430 | RAPID, PRECISE, NITRIC OXIDE ANALYSIS AND TITRATION APPARATUS AND METHOD - An apparatus for controlled delivery of nitric oxide uses a processor receiving inputs from a detector to control upstream introduction of the nitric oxide into breathing air. Improved accuracy and response speed are achieved by automatic control over a needle valve metering nitric oxide into breathing air. Also, a diverter vectoring a sample of the mixed air and nitric oxide toward a face of the detector reduces the diffusion boundary layer resulting in greater precision and speed of response. | 11-19-2015 |
20150342922 | CANNABINOD FORMULATION FOR THE SEDATION OF A HUMAN OR ANIMAL - A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery means which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery means to induce an incapacitating or immobilizing dose at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing a formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration. | 12-03-2015 |
20150352147 | Performance enhancing composition and use thereof - The performance of a mammal, manifested as a reduced oxygen uptake (VO | 12-10-2015 |
20150366901 | Methods of Treating Heart Failure - The present invention relates to the discovery that the administration of nitrate is an effective therapy for improving short-term and long-term outcomes in patients with heart failure, including heart failure with preserved ejection fraction (HFpEF). Thus, the present invention provides compositions and methods for the treatment or prevention of heart failure, including HFpEF, in a subject in need thereof. | 12-24-2015 |
20150374746 | PORTABLE, NITRIC OXIDE GENERATOR - An apparatus for portable delivery of nitric oxide without the need for pressurized tanks, power supplies, or other devices provides a single therapy session by triggering a heater to heat a reaction chamber. A piercing assembly may trigger to open sealed containers, such as bags, of liquid water or salt water in order to activate the heaters. Upon addition of liquid such as water or salt water to a chemically reactive heating element, heat is generated to activate the chemicals generating nitric oxide within a sealed reactor. Upon triggering, liquid containers are unsealed, the liquid drains down to initiate reaction of the heating chemicals, and the heat begins to penetrate the reactor. The reactor, in turn, heats its contents, which react to form nitric oxide expelled by the reactor to a line feeding a cannula for therapy. | 12-31-2015 |
20160008275 | TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME | 01-14-2016 |
20160008394 | INORGANIC NITRITE TO IMPROVE CARDIOPULMONARY HEMODYNAMICS | 01-14-2016 |
20160022731 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 01-28-2016 |
20160038533 | NITRITE FORMULATIONS AND THEIR USE AS NITRIC OXIDE PRODRUGS - Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided. | 02-11-2016 |
20160045537 | TREATMENT OF SKIN AND SOFT TISSUE INFECTION WITH NITRIC OXIDE - The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as | 02-18-2016 |
20160045538 | SYSTEMS AND METHODS FOR TREATMENT OF ACNE VULGARIS AND OTHER CONDITIONS WITH A TOPICAL NITRIC OXIDE DELIVERY SYSTEM - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045539 | METHODS AND SYSTEMS FOR TREATMENT OF INFLAMMATORY DISEASES WITH NITRIC OXIDE - The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045540 | TREATMENT AND PREVENTION OF LEARNING AND MEMORY DISORDERS - The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045541 | METHODS AND COMPOSITIONS FOR MUSCULAR AND NEUROMUSCULAR DISEASES - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045542 | COMPOSITIONS AND METHODS FOR TREATMENT OF OSTEOPOROSIS AND OTHER INDICATIONS - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045543 | TECHNIQUES AND SYSTEMS FOR TREATMENT OF NEUROPATHIC PAIN AND OTHER INDICATIONS - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160045544 | CANCER TREATMENTS AND COMPOSITIONS FOR USE THEREOF - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 02-18-2016 |
20160051579 | NITRIC OXIDE TREATMENT OF BOVINE RESPIRATORY DISEASE COMPLEX AND OTHER RESPIRATORY CONDITIONS - Methods, devices, and systems for treating a respiratory condition using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the respiratory condition may be bovine respiratory disease complex (BRDc). | 02-25-2016 |
20160057993 | PIGMENTED DECONTAMINATING GEL AND METHOD FOR DECONTAMINATING SURFACES USING SAID GEL - A decontamination gel is provided consisting of a colloidal solution comprising 0.1% to 30% by mass, preferably 0.1% to 25% by mass, still more preferably from 5% to 25% by mass, even more preferably 8% to 20% by mass, based on the mass of the gel, of at least one inorganic viscosifying agent; 0.1 to 10 mol/L of gel, preferably 0.5 to 10 mol/L of gel, still more preferably 1 to 10 mol/L of gel of at least one active decontamination agent; 0.01% to 10% by mass, preferably 0.1% to 5% by mass based on the mass of the gel of at least one mineral pigment; optionally, 0.1% to 2% by mass based on the mass of the gel, of at least one surfactant; optionally, 0.05% to 5% by mass, preferably 0.05% to 2% by mass, based on the mass of the gel, of at least one super-absorbent polymer; and the balance of solvent. | 03-03-2016 |
20160067279 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 03-10-2016 |
20160081962 | NUTRITIONAL OR DIETARY SUPPLEMENTS CONTAINING FATTY ACIDS AND NITRITE - Compositions including a fatty acid and a nitrite and/or nitrate composition and methods for using a fatty acid and a nitrite and/or nitrate composition for treatment of various conditions. | 03-24-2016 |
20160082040 | NITRIC OXIDE TREATMENT OF MAMMARY TISSUE - Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be mastitis. | 03-24-2016 |
20160136087 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES - The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 05-19-2016 |
20160136169 | SYSTEMS AND METHODS FOR DELIVERY OF TETRAHYDROBIOPTERIN AND RELATED COMPOUNDS - The present invention generally relates to compositions and methods for the delivery of tetrahydrobiopterin and/or related compounds through the skin. In general, tetrahydrobiopterin may react with oxygen, and various formulations discussed herein may prevent or reduce the ability of tetrahydrobiopterin to react with oxygen. For example, in some aspects, the tetrahydrobiopterin may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 05-19-2016 |
20160143274 | COMPOSITIONS AND METHODS WITH EFFICACY AGAINST SPORES AND OTHER ORGANISMS - Compositions and methods for the disinfection of surfaces are provided. The compositions include at least about 40 weight percent of a C | 05-26-2016 |
20160143986 | METHODS AND SYSTEMS FOR DELIVERY OF ZW1 HEPTAPEPTIDE - The present invention generally relates to systems and methods for the transdermal delivery of the heptapeptide ZW1. In some aspects, ZW1 may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 05-26-2016 |
20160151413 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS | 06-02-2016 |
20160158137 | HAIR TREATMENT SYSTEMS AND METHODS USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for transdermal delivery, and treatment of hair related conditions. The compositions can be used in a variety of applications, including causing or promoting hair growth and/or hair pigmentation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the scalp, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158276 | PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES USING SYSTEMS AND METHODS FOR TRANSDERMAL NITRIC OXIDE DELIVERY - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158277 | IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158278 | BRAIN AND NEURAL TREATMENTS COMPRISING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158279 | SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES - The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158310 | PEPTIDE SYSTEMS AND METHODS FOR METABOLIC CONDITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158370 | WOUND HEALING USING TOPICAL SYSTEMS AND METHODS - The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158371 | METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160158372 | CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION - The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 06-09-2016 |
20160166604 | Thiol-Sensitive Positive Inotropes | 06-16-2016 |
20160193336 | METHODS FOR USING NITRIC OXIDE IN A PLASMA STATE TO TREAT MEDICAL CONDITIONS AND DISEASES | 07-07-2016 |
20160199295 | TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME | 07-14-2016 |